Author’s reply to ‘Prevention of IVR: a need for investigation’

Author’s reply to ‘Prevention of IVR: a need for investigation’ Japanese Journal of Japanese Journal of Clinical Oncology, 2018, 48(3) 297 Clinical Oncology JJCO doi: 10.1093/jjco/hyx192 Advance Access Publication Date: 10 January 2018 Letter Letter Author’s reply to ‘Prevention of IVR: a need for investigation’ Shinichi Yamashita , Akihiro Ito, and Yoichi Arai Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan *For reprints and all correspondence: Shinichi Yamashita, Department of Urology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi Aoba-ku, Sendai, Miyagi 980-8574, Japan. E-mail: yamashita@uro.med.tohoku.ac.jp We appreciate your interest in our prospective, single-arm, multicen- for the upper urinary tract urothelial carcinoma (JCOG1403:UTUC ter clinical trial in which we showed that early ureteral ligation THP Phase III, UMIN000024267). In the study protocol, ureteral decreases the rate of intravesical recurrence (IVR) after radical ligation is performed during radical nephroureterectomy to avoid nephroureterectomy in patients with renal pelvic cancer (1). We the downstream tumor seeding (2). This might reveal the effect of applied propensity score-matching analysis to extract a historical ureteral ligation on IVR after radical nephroureterectomy. In add- control from the patients who underwent radical nephroureterect- ition, several subgroup analyses might be possible in the trial. omy for upper urinary tract urothelial carcinoma in the same group. Finally, early ureteral ligation is convenient in clinical practice. Our findings suggested that early ureteral ligation might help to pre- Therefore, we hope that this procedure will help to prevent IVR vent IVR after radical nephroureterectomy for renal pelvic cancer. after radical nephroureterectomy for renal pelvic cancer. Indeed, our study had some limitations, such as a small sample size. Thus, our findings should be confirmed by larger prospective Conflict of interest statement trials. In addition, 22 patients received intravesical instillation of pir- arubicin ((2′R)-4′-O-tetrahydropyranyldoxorubicin (THP) after rad- None declared. ical nephroureterectomy, which is now recommended to prevent IVR. However, such therapy had not been established when this study was started. We evaluated a subset of patients without THP References intravesical instillation to assess the distinct effect of early ureteral 1. Yamashita S, Ito A, Mitsuzuka K, et al. Efficacy of early ureteral ligation ligation and found that the 1- and 2-year IVR-free survival rates of on prevention of intravesical recurrence after radical nephroureterectomy patients with renal pelvic cancer with and without early ligation were for upper urinary tract urothelial carcinoma: a prospective single-arm 86 and 86%, and 73 and 61%, respectively (P = 0.033) (1). multicenter clinical trial. Jpn J Clin Oncol 2017;47:870–5. To start up a phase III trial to clarify the effects of early ureteral 2. Miyamoto K, Ito A, Wakabayashi M, et al. A phase III trial of a single early ligation in Japan is difficult. However, the Japan Clinical Oncology intravesical instillation of pirarubicin to prevent bladder recurrence after rad- Group has undertaken a phase III trial of a single early intravesical ical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403, instillation of THP to prevent IVR after radical nephroureterectomy UTUC THP Phase III). Jpn J Clin Oncol 2017 [Epub ahead of print]. © The Author(s) 2018. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 297 Downloaded from https://academic.oup.com/jjco/article-abstract/48/3/297/4797158 by Ed 'DeepDyve' Gillespie user on 16 March 2018 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Japanese Journal of Clinical Oncology Oxford University Press

Author’s reply to ‘Prevention of IVR: a need for investigation’

Free
1 page

Loading next page...
1 Page
 
/lp/ou_press/author-s-reply-to-prevention-of-ivr-a-need-for-investigation-hUFJzaR6UQ
Publisher
Oxford University Press
Copyright
© The Author(s) 2018. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
ISSN
0368-2811
eISSN
1465-3621
D.O.I.
10.1093/jjco/hyx192
Publisher site
See Article on Publisher Site

Abstract

Japanese Journal of Japanese Journal of Clinical Oncology, 2018, 48(3) 297 Clinical Oncology JJCO doi: 10.1093/jjco/hyx192 Advance Access Publication Date: 10 January 2018 Letter Letter Author’s reply to ‘Prevention of IVR: a need for investigation’ Shinichi Yamashita , Akihiro Ito, and Yoichi Arai Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan *For reprints and all correspondence: Shinichi Yamashita, Department of Urology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi Aoba-ku, Sendai, Miyagi 980-8574, Japan. E-mail: yamashita@uro.med.tohoku.ac.jp We appreciate your interest in our prospective, single-arm, multicen- for the upper urinary tract urothelial carcinoma (JCOG1403:UTUC ter clinical trial in which we showed that early ureteral ligation THP Phase III, UMIN000024267). In the study protocol, ureteral decreases the rate of intravesical recurrence (IVR) after radical ligation is performed during radical nephroureterectomy to avoid nephroureterectomy in patients with renal pelvic cancer (1). We the downstream tumor seeding (2). This might reveal the effect of applied propensity score-matching analysis to extract a historical ureteral ligation on IVR after radical nephroureterectomy. In add- control from the patients who underwent radical nephroureterect- ition, several subgroup analyses might be possible in the trial. omy for upper urinary tract urothelial carcinoma in the same group. Finally, early ureteral ligation is convenient in clinical practice. Our findings suggested that early ureteral ligation might help to pre- Therefore, we hope that this procedure will help to prevent IVR vent IVR after radical nephroureterectomy for renal pelvic cancer. after radical nephroureterectomy for renal pelvic cancer. Indeed, our study had some limitations, such as a small sample size. Thus, our findings should be confirmed by larger prospective Conflict of interest statement trials. In addition, 22 patients received intravesical instillation of pir- arubicin ((2′R)-4′-O-tetrahydropyranyldoxorubicin (THP) after rad- None declared. ical nephroureterectomy, which is now recommended to prevent IVR. However, such therapy had not been established when this study was started. We evaluated a subset of patients without THP References intravesical instillation to assess the distinct effect of early ureteral 1. Yamashita S, Ito A, Mitsuzuka K, et al. Efficacy of early ureteral ligation ligation and found that the 1- and 2-year IVR-free survival rates of on prevention of intravesical recurrence after radical nephroureterectomy patients with renal pelvic cancer with and without early ligation were for upper urinary tract urothelial carcinoma: a prospective single-arm 86 and 86%, and 73 and 61%, respectively (P = 0.033) (1). multicenter clinical trial. Jpn J Clin Oncol 2017;47:870–5. To start up a phase III trial to clarify the effects of early ureteral 2. Miyamoto K, Ito A, Wakabayashi M, et al. A phase III trial of a single early ligation in Japan is difficult. However, the Japan Clinical Oncology intravesical instillation of pirarubicin to prevent bladder recurrence after rad- Group has undertaken a phase III trial of a single early intravesical ical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403, instillation of THP to prevent IVR after radical nephroureterectomy UTUC THP Phase III). Jpn J Clin Oncol 2017 [Epub ahead of print]. © The Author(s) 2018. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 297 Downloaded from https://academic.oup.com/jjco/article-abstract/48/3/297/4797158 by Ed 'DeepDyve' Gillespie user on 16 March 2018

Journal

Japanese Journal of Clinical Oncology – Oxford University Press

Published: Mar 1, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

Try 2 weeks free now

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

or browse the journals available

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial

Interested in DeepDyve for your group?
Try 2 weeks free now